Download - Nemus Investor Presentation Feb 2017
NEMUS Bioscience OTCQB: NMUS February, 2017
2
Forward Looking Statement
This presenta-on contains “forward-‐looking statements” within the meaning of the “safe harbor” provisions of the Private Securi-es Li-ga-on Reform Act of 1995. All of the statements in this presenta-on, whether wriGen or oral, that refer to expected or an-cipated future ac-ons and results of NEMUS Bioscience, Inc. (NEMUS) are forward-‐looking statements. These forward-‐looking statements reflect the beliefs and expecta-ons of the management of NEMUS as of the date of this presenta-on. NEMUS cannot give any assurance that such forward-‐looking statements will prove to be correct. The reader is cau-oned not to place undue reliance on these forward-‐looking statements. The informa-on provided in this presenta-on does not iden-fy or include any risk or exposures, of NEMUS that would materially adversely affect the performance or risk of the company. For a descrip-on of the risks and uncertain-es related to the business of NEMUS, see our Annual Report on Form 10-‐K filed with the Securi-es and Exchange Commission and our subsequent periodic reports filed with the Securi-es and Exchange Commission. All informa-on contained in this presenta-on is provided as of the date of the presenta-on and is subject to change without no-ce. Neither NEMUS, nor any other person undertakes any obliga-on to update or revise publicly any of the forward-‐looking statements set out herein, whether as a result of new informa-on, future events or otherwise, except as required by law. This presenta-on does not convey an offer of any type and is not intended to be, and should not be construed as, an offer to sell, or the solicita-on of an offer to buy, any securi-es of NEMUS.
3
OTCQB NMUS
Price (2/7/17) $0.46/share 52-‐week high/low: $1.80/$0.30
Market Cap (2/7/17) $ 20.7 M on fully converted basis
Shares Outstanding 45 M if 100% fully converted
% Ownership by Directors & Officers 25.5% shares 1.2 M op-ons
Warrants Outstanding 11.5 M (Avg. Strike @ $0.40)
Founded 2012
Base of Opera-ons Costa Mesa, California & Oxford, Mississippi
Company Overview
NEMUS Bioscience is a publicly traded, life-‐science biotech company, focused on developing regulatory-‐approved, cannabinoid-‐based therapies, for a
spectrum of diseases, especially those of unmet medical need
4
NEMUS Value ProposiMon: DisrupMng the cannabinoid therapeuMc space • NEMUS is developing cannabinoid molecules for the treatment and/or management of
acute and chronic diseases, especially those of unmet medical need
• NEMUS is the sole development and commercializaMon partner of the University of Mississippi, drawing on 48 years of intellectual capital in cannabinoid chemistry and physiology from the only enMty with a Federal license to directly study cannabinoids
• NEMUS is advancing therapeuMcs for medical applicaMons in, to our knowledge, global mulM-‐billion dollar markets including:
ü The only cannabinoid company advancing therapeuMc plaRorms for mulMple indicaMons in ophthalmology
ü The only cannabinoid company advancing mulMple therapeuMc plaRorms for anM-‐infecMve uses against bacteria and viruses
ü The only cannabinoid company with re-‐engineered prodrugs and analogues of cannabinoids designed for mulMple routes of administraMon
ü The only cannabinoid company with potenMal cost-‐effecMve and enhanced life-‐cycle producMon related to biosyntheMc manufacturing of cannabinoids
• Proprietary product pipeline has a global patent footprint including largest pharma markets of USA, Japan and the EU.
5
Nemus Cannabinoid Development PorRolio
Drug Candidate Target IndicaMons Projected Global
Market Size
Developmental stage
NB1111 (Prodrug THC) Glaucoma $8 B 1 Pre-‐Clinical
NB1222 (Prodrug THC) Chemotherapy-‐Induced Nausea and Vomiting (CINV) $2 B 2 Pre-‐Clinical
NB2111 (Analogue CBD) Chemotherapy-‐Induced Peripheral Neuropathy (CIPN);
pain syndromes
>$30 B 3 Research
NB2222 (Analogue CBD) Ocular Targets: uveitis, dry eye syndrome, macular degeneration, diabetic
retinopathy
> $22 B Research
Cannabinoid Plalorm NB3111
Methicillin-‐resistant Staph aureus (MRSA); gram-‐posi-ve
bacteria; viral species
>$6 B 4 Research
1. IMS Midas data; 2015 2. Transparency Market Research, 2014 3. Transparency Market Research, 2016 4. Pew Trust MRSA Survey, 2012
6
NEMUS Recent Milestones Recent Milestones
• December 2015: NEMUS in-‐licenses CBD deriva-ves from UM and ini-ates research into chemotherapy induced peripheral neuropathy (CIPN)
• January 2016: NEMUS announces valida-on of NB1111 data in glaucoma with 45% decline in IOP as NEMUS becomes leading cannabinoid drug developer in ophthalmology
• January 2016: NEMUS announces ini-a-on of development program for chemotherapy-‐induced nausea and vomi-ng (CINV)
• February 2016: NEMUS signs agreement with AMRI to manufacture proprietary API for glaucoma (NB1111) and CINV (NB1222) programs
• June 2016: NEMUS announces successful iden-fica-on of CBD-‐like candidate molecule (NB2111) with significant analgesic ac-vity versus morphine in validated animal CIPN study;
• • July 2016: Glaucoma study confirms >40% decline in IOP correla-ng decline to THC concentra-on in IOP-‐regula-ng
ocular -ssues; study confirms presence of THC in all major ocular compartments; no THC found in plasma
• July 2016: patent issued in Australia for NB1111/NB1222 THC prodrug
• August 2016: murine tac-le allodynia study reveals dose-‐escala-on of CBD deriva-ve molecule delivers comparable analgesia safely in validated pain model versus morphine
• As of today, we license two U.S. patents as well as foreign counter-‐parts in Japan, the European Union, Australia
7
June, 2016: Nemus collaborates to “disrupt” the cannabinoid market
• Nemus is dedicated to “disrup-ng” the cannabinoid space by introducing prodrug and analogue versions of cannabinoids that are designed to improve efficacy and safety versus naturally derived counterparts
• Nemus signed a defini-ve license agreement with Teewinot Life Science Corp. and AMRI to manufacture biosynthe-cally produced cannabinoid molecules based on Nemus’ proprietary prodrug/analogue technology
• Nemus believes biosynthe-cally produced cannabinoids offer significant cost-‐efficient manufacturing and enhanced produc-on scheduling not associated with plant-‐derived or chemically synthesized produc-on
• The collabora-on with Teewinot will permit Nemus to produce both major (THC and CBD) and minor cannabinoids for development as both poten-al second-‐ and third-‐genera-on cannabinoid-‐based therapies tailored for routes of administra-on that could op-mize efficacy and safety during therapy
8
NEMUS Proprietary Cannabinoid Drug Programs Hold CompeMMve Advantages Orally administered cannabinoids (both pill and spray delivery mechanisms) hold a variety of disadvantages for paMents: • Poor bioavailability vs other routes of administraMon • Irregular pharmacokineMcs secondary to GI absorpMon • SuscepMble to significant first-‐pass metabolism by the liver • Regulatory findings of oral and sublingual spray delivery:
– “Due to extensive first-‐pass metabolism and high lipid
solubility, a frac-on of the drug reaches the circula-on”1
– “The pharmacologic effects of Marinol are dose-‐related and subject to considerable inter-‐pa-ent variability”1
– “Intoxica-on type reac-ons appear dose-‐related due to great inter-‐pa-ent drug level variability” 2
– “The pharmacokine-c data show great inter-‐subject variability”3
1) Marinol Summary Basis of Approval 2) Sa6vex Product Labelling -‐ Black Box Warning 3) Sa6vex Product Labelling
NEMUS prodrug technology designed to capitalize on the use of proprietary formulaMons that could allow for alternaMve delivery methods miMgaMng risk of unpredictable plasma levels that can compromise safety and efficacy
9
InnovaMve Cannabinoid FormulaMons Designed for Improved Drug Delivery
-‐
• Ocular delivery: Glaucoma & re-nal diseases • Transmucosal delivery: CINV & CIPN (suppository &
buccal patch)
• Transmembranous delivery: An--‐infec-ves (An--‐MRSA) (nasal/transdermal/ transmembraneous delivery)
All NEMUS licensed delivery opMons opMmize our prodrug cannabinoid technology by enhancing bioavailability by avoiding
first-‐pass liver metabolism and offering more predictable pharmacokineMcs
10
• The University of Mississippi (UM) is the only enMty in the US authorized by NIDA and the DEA to cul-vate cannabis on behalf of the federal government for more than 49 years
• NEMUS has exclusive, perpetual, worldwide exclusivity for all compounds and targets we are working on with UM for key fields of delivery
• Patents have been issued for the proprietary prodrug of THC in the USA (2014), Japan (2015), Australia (2016); EU (2017); patents pending in Canada, and Hong Kong.
• A recent DEA finding that CBD derived from any source is a Schedule I substance likely has liGle direct impact on Nemus given the underlying patent estates licensed by the Company for therapeuMc development of cannabinoids
• Nemus and the University are currently engaged in the development of third-‐generaMon hybrid syntheMc cannabinoid molecules with the goal of becoming the leading developer of second-‐ and third-‐generaMon compounds in the field of cannabinoid-‐related medicines
Exclusive strategic relaMonship with the University of Mississippi provides access to a diverse cannabinoid patent estate
11
NB1111 For the Treatment of
Glaucoma
12
Physical Challenges to Ocular Drug Delivery
• Blood-‐re-nal barrier • Blood-‐aqueous humor barrier • Corneal-‐scleral barrier
• Most effec-ve route into the eye for lipophilic cannabinoids is to re-‐engineer the molecule so it effec-vely traverses the cornea
13
The Glaucoma Market
• $8 billion globally and growing with aging popula-ons • A leading cause of blindness in the US • $2.3 billion US market (32 MM Rx) • Regulatory pathway well-‐defined • Regulatory strategy: Poten-al for “urgent medical need” and “breakthrough therapy” FDA designa-ons;
• Glaucoma as a “Non-‐responder” market presents greater opportuni-es; >50% of pa*ents on 2 or more Rx
• Cannabinoids have shown neuroprotec-ve quali-es in vitro and in vivo (mul-ple animal species) related to the op-c nerve
• Licensing and acquisiMons in the glaucoma market occur predominantly earlier in development (pre-‐clin, phase 1)
14
NB1111 (Glaucoma/Ophthalmology)
Sustained release treatment with a proprietary THC prodrug in a solid lipid nanoparMcle (SLN) could bring a new therapeuMc class directly to the target
organ, avoiding systemic exposure
OCULAR FEATURES OF NB1111 • Penetrates mul-ple chambers of the eye • Produces a 45% reduc-on in Intra-‐Ocular Pressure (IOP) in glaucoma animal model (THC has been shown to lower IOP in previous human tes-ng) • ReducMon of IOP is the only proven method to manage damage to the op-c nerve in glaucoma • PotenMally first medicaMon to exert direct neuroprotec-on of the op-c nerve (re-nal ganglion cells; RGCs) by inhibi-ng apoptosis pathway • NeuroprotecMon is the “holy grail” of glaucoma • Cannabinoids have been shown to possess neuroprotecMve quali-es by disrupMng the apoptosis cycle that kills re-nal ganglion cells (RGCs): the glutamate-‐NMDA pathway
The proprietary formulaMon allows THC to be absorbed across membranes that are normally barriers to absorpMon
15
THCVHS (prodrug) vs THC IOP reducMon over Mme profile: Prodrug achieves significant decline in IOP using SLN (solid lipid nanoparMcle) technology
16
Superior reducMon in IOP by THCVHS versus THC explained by enhanced Mssue penetraMon into organs regulaMng IOP in rabbit glaucoma model
• THC administered in an SLN showed no appreciable concentra-on in ocular -ssues regula-ng IOP
• THCVHS (prodrug of THC) shows -ssue penetra-on into ocular organs regula-ng IOP and the re-na at 3 hours post-‐administra-on
17
Ocular Mssue concentraMon of THCVHS at 60 min and 120 min post-‐dose in normal rabbit eyes
• Drug localizes to ocular organs responsible for IOP regula-on • No THC detected in the plasma of the study animals even ater 5
days of dosing ABBREVIATION
KEY
AH = aqueous humor IC = iris/ciliary body VH = vitreous humor RC = re-noid/choroid CON-‐IC: corneal/ iris space
18
THC Lowers IOP in Humans; PredicMve Animal Model Consistent with Human Experience
• The acMve moiety of NB1111, THC, has been shown to lower IOP in mul-ple human studies • THC delivered by inhala-on (smoking) or edible lowered IOP 40% to 65% but compromises blood flow to re-na via systemic vasodila-on and dosing complicated by short half-‐life
• The NEMUS prodrug NB1111 achieved a 45% reduc-on in IOP using emulsion eye drop in validated rabbit glaucoma model tes-ng conducted at UM
• New formulaMon evaluaMon of NB1111 will confront the compliance issue of topical drops (eyedrops) by assessing development of embedding the drug into an implantable matrix (contact lens) for sustained release • Current eyedrop data using SLN technology poin-ng to BID dosing
• Next stage tesMng: • Human studies looking at IOP lowering effect as single ascending dose (SAD) and mul-ple ascending dosages (MAD)
19
THC Can Address MulMple MOAs in Lowering IOP and Preserving ReMnal Ganglion Cells (RGCs) Therapy Class
Mechanism of Ac-on (MOA)
Increased flow trabecular mesh
Increased flow uveoscleral pathway
Decreased fluid produc-on
Direct neuroprotec-ve
quali-es
Prostaglandins (50% mkt share)
X
β-‐ adrenergic blockers (30%)
X
α-‐ adrenergic agonists (10%)
X X
Carbonic anhydrase inhibitors (<5%)
X
Cholinergic agonists (<5%)
X
Pro-‐drug THC (NB1111)
X X X X
20
NB1222
Treatment of Chemotherapy-‐Induced
Nausea and Vomi-ng (CINV)
21
NB1222: Chemotherapy-‐Induced Nausea and VomiMng (CINV)
• There are an es-mated 15 million cancer cases globally according to the Interna-onal Agency for Research on Cancer
• 25%-‐30% of pa-ents receive chemotherapy; of the chemotherapy recipients, 70%-‐80% experience CINV
• The global CINV market exceeds $2 B*
• Dronabinol is an orally administered synthe-c version of THC approved for cachexia in HIV and nausea/vomi-ng in CINV with annual sales for CINV in excess of $110 MM (Source: IMS Health)
• NEMUS plans to iniMally develop a suppository version of our proprietary prodrug of THC, NB 1222, for use in CINV by filing an NDA via the expedited regulatory pathway of 505(b)(2)
* Transparency Market Research, 2014
22
NB1222 Advantages Versus Dronabinol in CINV
-‐1
4
9
PD 1 3 5 7 9 11 13 15 17 19 21 23
Plasma Co
ncen
traM
ons (ng/
ml)
Timepoint (h)
A Comparison of THC Plasma ConcentraMons From ProDrug THC Suppository* vs. dronabinol in Humans
Dronabinol 10 mg THC 10 mgEg
• Bioavailability: Dronabinol has been found to have a bioavailability of 6%-‐15% while a prodrug of THC administered via suppository yielded a bioavailability of roughly 70%*
• AbsorpMon: Orally administered dronabinol can have erra-c absorp-on from the gut coupled to varying plasma levels due to first-‐pass metabolism in the liver; a suppository avoids the upper GI tract and thereby de-‐risks the nega-ve effect of first-‐pass metabolism on the drug pharmacokine-cs
• Adverse Events: Oral dronabinol has been associated with nausea and vomi-ng adverse events; a suppository route of administra-on mi-gates that side effect
• PharmacokineMcs: THC prodrug dosing using a suppository allows greater drug exposure (graph above) and maintenance within the therapeu-c window versus peak/trough PK with oral dosing
Source: NEMUS Internal Data
23
PotenMal buccal delivery of NB1222 for CINV
Buccal Transmucosal Delivery Offers Another Route of Administra-on for
Cannabinoid-‐Based Medica-ons Avoiding First-‐Pass Metabolism in the Liver
• Reliable delivery to -ssues • Op-mal route of delivery for prodrugs • More reliable pharmacokine-cs • Enhanced biodistribu-on • Exclusive global license held by Nemus
24
Advantages of Buccal Mucosal Drug Delivery
• Avoids first pass effect • Avoids chemically hos-le GI environment • Allows use of drugs with short half-‐life or highly potent drugs • Can interrupt drug input if adverse events develop • Readily accessible; easy pa-ent administra-on • Robust -ssue (High cellular turnover, rou-nely exposed to exogenous compounds) • Precise dosage form localiza-on
25
CHEMOTHERAPY-‐INDUCED PERIPHERAL NEUROPATHY (CIPN)
NB2111: an analogue of CBD
26
Chemotherapy-‐Induced Peripheral Neuropathy (CIPN): Market Data • CIPN is a dose-‐dependent complica-on associated with many types of
chemotherapeu-c agents
• In addiMon to severe, someMmes unreminng pain, it can also lead to premature discon-nua-on of chemotherapy compromising cancer cure rates.
• No agents have been shown to prevent CIPN. There is an unmet medical need for therapies that can mi-gate pain without complica-ons like addicMon and gastrointesMnal obstrucMon
• The CIPN market in the United States exceeds $500 MM (LifeSci Advisors, 2013) and the parallel opioid-‐induced cons-pa-on market is es-mated to be $600 MM globally (GlobalData, 2015)
• The overall global pain market is projected to approach be $83 billion by 2024*
• The market is searching for “abuse resistant” analgesic alternaMves * Transparency Market Research, 2016
27
NB2111: exhibits significant analgesia
• NEMUS has signed a research agreement with UM to screen mul-ple CBD-‐related deriva-ves in validated animal models of CIPN
• NB2111 is an analogue of CBD that has been tested in a murine model of tac-le allodynia replica-ng the neuropathy associated with exposure to the chemotherapeu-c agent of cispla-n (used in lung, breast and colon cancers)
• NB2111 resulted in significant analgesia in this model with analgesic coverage commensurate with that seen using the highest dose of morphine exposure
• Next steps in development include advancing the tes-ng to assess maximum tolerable dose in animal studies and developing the formula-on of the compound to make it suitable for parenteral and non-‐parenteral dosing
• NEMUS and UM will con-nue assessing other forms of CBD deriva-ves in an effort to develop therapeuMc opMons for mulMple types of pain syndromes (e.g. migraine) and possible anM-‐addicMve uses to combat the global opioid addic-on crisis
28
METHICILLIN-‐RESISTANT STAPHYLOCOCCUS AUREUS
MULTIPLE CANNABINOID
DERIVATIVES
29
MRSA Has Become a Global Urgent Health Concern
30
Methicillan-‐Resistant Staph Aureus (MRSA)
MRSA FACTS & CURRENT MEDICAL LANDSCAPE • First described in 1961 now a pandemic • CDC: prevalence of MRSA in ICU se|ng approaching 60% • 1960’s: one gene-c MRSA muta-on/clone; currently six MRSA gene-c clones; 15 clones in China • 2010 hospital survey: 61.8% of pa-ents admiGed to ICU were MRSA colonized1
• 50% of screened pa-ents had healthcare-‐associated infec-ons1 • 11,000 deaths annually; 80,000 invasive infec-ons/yr.2 • Annual costs in the US: $3.2 -‐ $4 billion2
1) Jarvis WR et al; Am J Infect Control 2012; 40(3): 194-‐200 2) Pew Trust MRSA Survey; April 3, 2012
31
Methicillan-‐Resistant Staph Aureus (MRSA)
NEMUS is Assessing a New Class of AnM-‐InfecMves to Combat the Threat of AnMbioMc-‐AnMviral Resistance
CANNABINOID EXPERIENCE IN MRSA1
• Select cannabinoids have been known to possess an-bacterial proper-es 1 • Nemus has successfully screened the bactericidal acMvity of a library of individual cannabinoids against mulMple strains of MRSA • Nemus has iden-fied cannabinoid cocktails with significant synergisMc bactericidal acMvity against MRSA • Nemus intends to assess the ac-vity of a library of syntheMc cannabinoid molecules to treat MRSA with the goal to broaden the IP estate against bacteria and viruses • Nemus an-cipates partnering the gram-‐posi-ve an--‐microbial plalorm in the H1’2017 -meframe to accelerate development of these compounds
1) J Nat Prod. 2008 Aug;71(8):1427-‐30. doi: 10.1021/np8002673. Epub 2008 Aug 6. -‐ An-bacterial cannabinoids from Cannabis sa-va: a structure-‐ac-vity study
32
The MRSA market in 2017
• The MRSA therapeu-c space is designed to combat mul-ple species of MRSA based on virulence and anatomical loca-on of infec-on
• Community-‐acquired MRSA (CA-‐MRSA) is the most prevalent type and s-ll growing in incidence
• Health-‐care acquired MRSA (HA-‐MRSA; formerly hospital-‐acquired MRSA) s-ll poses a risk, especially for immuno-‐compromised pa-ents and post-‐surgical infec-ons, but prevalence declining
• Mupirocin-‐resistant MRSA (Mup-‐MRSA) is a specie resistant to the an-bio-c mupirocin (Bactroban™) used to decolonize pa-ents found to carry MRSA on their skin or nares
• Global MRSA therapeu-cs market in 2011 $2.67 billion with forecasts projec-ng growth to $3.47 billion by 2019 (CAGR 3.4%)*
* GlobalData: Research & Markets report on MRSA; June, 2012
33
Methicillan-‐Resistant Staphylococcus Aureus (MRSA)
CANNABINOID EXPERIENCE IN MRSA1
• Select cannabinoids have been known to possess some an-bacterial proper-es 1 • Nemus has successfully screened the bactericidal acMvity of a library of individual cannabinoids against mulMple strains of MRSA • Nemus has iden-fied cannabinoid cocktails with significant synergisMc bactericidal acMvity against MRSA • Nemus intends to assess the ac-vity of a library of syntheMc cannabinoid molecules to treat MRSA with the goal to broaden the IP estate • Nemus an-cipates partnering the gram-‐posi-ve an--‐microbial plalorm in the H1’2017 -meframe to accelerate development of these compounds
1) J Nat Prod. 2008 Aug;71(8):1427-‐30. doi: 10.1021/np8002673. Epub 2008 Aug 6. -‐ An-bacterial cannabinoids from Cannabis sa-va: a structure-‐ac-vity study
NEMUS is Assessing a New Class of AnM-‐InfecMves to Combat the Threat of AnMbioMc Resistance
34
AnM-‐microbial acMvity of cannabinoids
• An-microbial ac-vity of single agents is oten assessed with an assigned value called the minimum inhibitory concentra-on (MIC); the lower the MIC, the more potent the killing ac-vity of the molecule
• When agents are combined for an--‐microbial effect, a potency value assessed is the frac-onal inhibitory concentra-on (FIC); the lower the FIC value, the more potent the combina-on of the two agents – synergy exists
• When the FIC value is < 1.0 there is synergy, the compounds exert inhibitory effects on the bacteria more than the sum of their effects alone
• If the FIC is < 0.5, this indicates highly synergis-c killing
• NEMUS proprietary cannabinoid cocktails exert significant killing power against mulMple species of MRSA with in vitro experiments demonstraMng FIC data consistently < 0.3
35
NEMUS Bioscience, Inc. (OTCQB: NMUS)
• NEMUS is focused on developing cannabinoid molecules for the treatment and management of acute and chronic diseases, especially those of unmet medical need
• NEMUS cannabinoid molecules are engineered to enhance trans-‐membrane transport resulMng in: ü Enhanced bioavailability ü Permits routes of administra6on that avoid first-‐pass metabolism by the liver ü Resul6ng in more predictable pharmacokine6cs ü Patents issued 2014-‐2016 allow long IP runway with broad claims and reach for the
delivery of molecules and condi6ons that can be treated
• NEMUS is the sole development and commercializaMon partner of the University of Mississippi, drawing on almost 50 years of intellectual capital in cannabinoid chemistry and physiology
• NEMUS is advancing therapeuMcs for medical applica-ons in global mul--‐billion dollar markets including a cannabinoid franchise in ophthalmology, palliaMve care in oncology, and anM-‐infecMve medicines, especially in strains developing resistance to an-bio-cs
36
Management
BRIAN MURPHY, MD, MPH, MBA – Chief ExecuMve Officer; Chief Medical Officer, Director Dr. Murphy has almost two decades of experience in drug development and evalua-on, both from the academic and industry perspec-ve. He most recently served as the CMO of Eiger Biosciences. Previously, Dr. Murphy was CMO at Valeant Pharmaceu-cals Interna-onal (VRX) where his responsibili-es also included oversight of Global Medical Affairs and Pharmacovigilance. Dr. Murphy also served as Medical Director, then VP of Marke-ng and Commercial Strategy of Hepatology for InterMune, Inc. (ITMN). Prior to InterMune, Dr. Murphy was Medical Director of North America for An-virals/Interferons at Hoffmann-‐LaRoche. Murphy is board-‐cer-fied in internal medicine and completed his residency at Tuts-‐New England Medical Center. He went on to complete parallel fellowship tracts at Harvard Medical School and the MassachuseGs General Hospital. Dr. Murphy earned his MD, MPH (general public health), and MS (pharmacology) degrees from New York Medical College and is a graduate of the Harvard School of Public Health (MPH in Health Policy and Management). He earned his MBA at the Columbia University Graduate School of Business.
LIZ BERECZ, MA, CPA -‐ Chief Financial Officer Elizabeth Berecz is a seasoned financial execu-ve with over 20 years of experience holding senior level posi-ons in both private and public companies. She has proven success in leading strategic planning, financial repor-ng, and global system implementa-ons for companies of various sizes. Liz started her career at Price Waterhouse Silicon Valley where she spent five years audi-ng several high profile public companies in the technology industry. She then spent 10 years holding key leadership posi-ons in various publicly held Companies including Quantum Corpora-on (Corporate Controller), Business Objects (VP Finance and Administra-on), and Excite (VP Finance), followed by 10 years of key leadership roles in privately held Companies including CFO posi-ons with Op-cal Shop Interna-onal, StarTrac Inc., Power Balance Technologies, Inc. and most recently Bentley Mills, Inc. She also serves as an Adjunct Professor of Accoun-ng and Finance at the University of San Francisco. Elizabeth received her BA in Economics from Stanford University and a MA in Sports Management from University of San Francisco.
37
Management
COSMAS N. LYKOS, ESQ – Co-‐founder, Officer & Board Member – ExecuMve Chairman Cosmas Lykos co-‐founded NEMUS in 2012 and has served as its Chairman of the Board of Directors since August 2014. Ater gradua-ng with Honors from Duke University School of Law in 1993, Mr. Lykos began his career at Gibson Dunn & Crutcher, LLP, an interna-onal full-‐service law firm, as a corporate associate un-l 1998. From 1998 to 2004, Mr. Lykos served as Vice President of Business Affairs, General Counsel, Secretary and Chief Compliance Officer of RemedyTemp, Inc., a NASDAQ publicly-‐traded temporary staffing firm with over 250 directly-‐owned and franchised offices na-onwide. From 2004 un-l 2008, Mr. Lykos served as Vice President of Business Development, Chief Legal Officer, Secretary and Chief Compliance Officer of Oakley, Inc., a NYSE publicly-‐traded sports and technical eyewear, apparel, accessories and retail company. In January of 2008, he became Co-‐owner and President of the Op-cal Shop Interna-onal, a designer and distributor of licensed eyewear brands, including Chrome Hearts and Blinde, through two wholly-‐owned foreign subsidiaries with a direct and distributor sales network in over 60 countries around the world. Primary responsibili-es included developing and implemen-ng OSI’s vision and strategies and the management of its foreign subsidiaries, sales, legal, human resources, finance and administra-ve func-ons. In 2011, Mr. Lykos nego-ated and consummated the sale of OSI to its primary licensor, Chrome Hearts LLC and con-nues to provide consul-ng services. Mr. Lykos has extensive public and private company board of directors experience. As Chief Compliance and Legal Officer and Secretary of both Oakley, Inc. and RemedyTemp, Inc., Mr. Lykos aGended all board of director mee-ngs and board commiGee mee-ngs. As an angel investor, Mr. Lykos has made minority investments in various private companies and has served on their Board of Directors.
38
BOD & Strategic Advisors
MAHMOUD A. ELSOHLY, PHD ScienMfic Advisor World’s foremost expert on the science of cannabinoids. 300+ scien-fic publica-ons . Research professor at The University of Mississippi.
JERRY MCLAUGHLIN, MBA Strategic Advisor, Board of Directors -‐ Member CEO of AgeneBio; 25 year veteran execu-ve in pharmaceu-cal medical device and healthcare related industries (Endo Pharma, Merck, MBA-‐ Villanova University,BA-‐ Dickinson College).
TOM GEORGE Board of Directors – Chairman of Audit Commivee
30 year senior execu-ve in corporate finance and accoun-ng; CFO of Deckers Brands ( Ophthonix, Oakley, Coopers & Lybrand). Graduate of University of Southern California.
DOUGLAS S. INGRAM, ESQ Board of Directors – Vice Chairman, Chairman of CompensaMon Commivee 25 year senior execu-ve in healthcare, Past President of Allergan, former AGorney at Gibson, Dunn & Crutcher, LLP. Summa cum laude and Order of the Coif graduate of the Univ. of Arizona school of law.
DONALD I. ABRAMS, M.D. ScienMfic Advisor Chief, Hematology/Oncology at UCSF Cancer and Integra-ve Medicine specialist with research interests in the development of an--‐cancer therapeu-cs and pallia-ve care medicines.
39
Contact
600 Anton Blvd., Suite 1100
Costa Mesa, CA 92626 949-‐396-‐0330
[email protected] www.nemusbioscience.com
Investor RelaMons: Adam Holdsworth PCG Advisory Group Tel: 646-‐862-‐4607 [email protected]
Company: Brian Murphy, MD, MPH, MBA CEO -‐ CMO Tel: 949-‐355-‐1140 [email protected]